← Back to Search

Device

Spinal Stimulation for Spinal Cord Injury (SCI Trial)

N/A
Recruiting
Led By Gail F Forrest, PhD
Research Sponsored by Kessler Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Exhibits at least one of the following hypotensive symptoms: Baseline hypotension - resting supine or seated SBP < 90mmHg; SBP drop ≥ 20 mmHg within 5 minutes of assuming seated position; Symptoms of orthostasis with a drop of SBP (<90mmHg) from supine to sitting.
Injury level ≥T2 (thoracic level)
Must not have
Significant coronary artery or cardiac conduction disease, a recent history of myocardial infarction
Ventilator-dependent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up will be performed every 5 minutes during the orthostatic tests, average of 2 weeks

Summary

This trial aims to evaluate if spinal stimulation can stabilize blood pressure and reduce symptoms of orthostatic hypotension in individuals with spinal cord injury.

Who is the study for?
This trial is for individuals with acute spinal cord injury (7-30 days post-injury) at or above the T2 level, who experience low blood pressure symptoms. They must have an AIS grade of A-C and not be on new cardiac meds within the last 5 days. Exclusions include current severe illness, pregnancy, mental incapacity to consent, cancer, ventilator dependence, history of stimulators or pacemakers/defibrillators.
What is being tested?
The study tests if transcutaneous spinal stimulation can stabilize blood pressure in acute SCI patients during orthostatic challenges (moving from lying down to sitting up). It compares 'optimal' stimulation settings against a 'sham' placebo-like treatment to see which is better at preventing drops in blood pressure.
What are the potential side effects?
Potential side effects may include discomfort at the stimulation site and possible skin irritation due to electrodes. Since it's a non-invasive procedure, serious side effects are unlikely but monitoring will occur for any unexpected reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I experience low blood pressure or symptoms when I stand up.
Select...
My spinal cord injury is at or above the T2 level.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had a recent heart attack or serious heart disease.
Select...
I rely on a machine to help me breathe.
Select...
I am unable to understand and consent to the trial on my own.
Select...
I currently have an illness or infection that could affect my treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~will be performed every 5 minutes during the orthostatic tests, average of 2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and will be performed every 5 minutes during the orthostatic tests, average of 2 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Orthostatic symptoms when stimulation is applied
Optimal stimulation frequency
Optimal stimulation sites
+1 more
Secondary study objectives
Additional hemodynamic measure - diastolic blood pressure
Additional hemodynamic measure - heart rate
Electromyography (EMG) of leg muscles - muscle activation (analysis of mean and peak amplitudes)
+5 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Optimal stimulation (for a blood pressure response)Active Control3 Interventions
Stimulation will be applied during an orthostatic sit-up challenge, using the profile (stimulation site and parameters) that was chosen in the mapping sessions, for optimal modulation of systolic blood pressure.
Group II: Sham stimulationPlacebo Group3 Interventions
Sham stimulation will be applied during an orthostatic sit-up challenge. Sham stimulation will be delivered at a predetermined spinal location. Stimulation parameters, however, will be different from those chosen for the optimal stimulation, and sensation may be different as well.

Find a Location

Who is running the clinical trial?

Kessler FoundationLead Sponsor
181 Previous Clinical Trials
11,067 Total Patients Enrolled
Gail F Forrest, PhDPrincipal InvestigatorKessler Foundation
4 Previous Clinical Trials
155 Total Patients Enrolled

Media Library

Biostim-5 transcutaneous spinal stimulation (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05731986 — N/A
Central Nervous System Disorders Research Study Groups: Optimal stimulation (for a blood pressure response), Sham stimulation
Central Nervous System Disorders Clinical Trial 2023: Biostim-5 transcutaneous spinal stimulation Highlights & Side Effects. Trial Name: NCT05731986 — N/A
Biostim-5 transcutaneous spinal stimulation (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05731986 — N/A
~5 spots leftby Nov 2025